Wedmont Private Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wedmont Private Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$222K	Buy	+4,048	New	+$255K	0.01%	919
2026 Q2	–	Sell	-4,084	Closed	-$234K	–	959
2026 Q1	$234K	Buy	+4,084	New	+$238K	0.01%	756
2025 Q4	–	Sell	-4,201	Closed	-$230K	–	809
2025 Q3	$230K	Sell	4,201 -191	-4%	-$10.9K	0.01%	706
2025 Q2	$262K	Buy	+4,392	New	+$259K	0.01%	627
2025 Q1	–	Sell	-6,376	Closed	-$430K	–	708
2024 Q4	$430K	Buy	+6,376	New	+$427K	0.02%	431

Other funds holding BMRN

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Wedmont Private Capital's BMRN Position: Q3 2026 in Review

Wedmont Private Capital opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 4,048 shares worth $222K. The stake represents 0.01% of the portfolio and ranks #919 among its holdings. This is a return to the name: Wedmont Private Capital previously reported a position in BMRN as recently as Q1 2026.

Wedmont Private Capital first reported a position in BMRN in Q4 2024 and has held it in 5 quarters since. The position peaked at $430K in Q4 2024. 22 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Wedmont Private Capital held 4,048 shares of BioMarin Pharmaceuticals worth $222K as of Q3 2026.
BioMarin Pharmaceuticals was a new Wedmont Private Capital position in Q3 2026.
BioMarin Pharmaceuticals made up 0.01% of Wedmont Private Capital's portfolio in Q3 2026, its #919 holding.
Wedmont Private Capital first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Wedmont Private Capital's BioMarin Pharmaceuticals position peaked at $430K in Q4 2024.
22 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Wedmont Private Capital's 13F filing for Q3 2026, filed 9 Oct 2026.